 |
|
Approach to the Treatment of Limb Disorders With Botulinum Toxin AExperience With 187 Patients
Seth L. Pullman, MD, FRCPC;
Paul Greene, MD;
Stanley Fahn, MD;
Sara F. Pedersen, MS
Arch Neurol. 1996;53(7):617-624.
Abstract
Objective
To determine the dosing, response expectation, efficacy, and most rational strategy for using intramuscular injections of botulinum toxin A (BTX) for limb disorders.
Design
Open-label prospective analysis of outcome after BTX treatment in patients with limb disorders.
Procedure
Botulinum toxin A prepared from lyophilized botulinum toxin was injected into selected upper and lower limb muscles under electromyographic guidance. Booster injections were given every 10 to 14 days during the first month (if needed) until optimal effects were achieved. Clinical data and muscle strength testing were obtained before the first injections and repeated at each visit. Level of disability, global functional improvement, and relief of pain were evaluated 6 to 8 weeks after the first set of injections. Practical and meaningful BTX doses by muscle, limb, or condition according to specified levels of efficacy were developed.
Main Outcome Measures
Botulinum toxin A efficacy was calculated as an arithmetic combination of changes in the 3 clinical ratings before and after administration of BTX.
Results
Botulinum toxin A injections were given to 187 patients with limb disorders during an 8-year period (136 with dystonia, 37 with parkinsonian, essential, and cerebellar tremors, and 14 with spasticity). Four overall outcomes from no effect to almost complete improvement in the use of the limb or relief of pain were found, and determined the strategy for follow-up injections. Average BTX efficacy for all patients was 65% and ranged from 83.5% for focal hand dystonia to 35.7% for parkinsonian tremor. Botulinum toxin A injections relieved pain, independent of motor function, in 82.7% of patients with painful muscle spasms.
Conclusions
Botulinum toxin A was found to be a safe and useful treatment of various limb conditions. Botulinum toxin A was significantly more effective when only a few muscles needing low doses were injected, and tended to be more useful in dystonia and spasticity than tremor. Candidates for BTX injection could be categorized functionally into 3 groups independent of the underlying disorder. The only significant adverse effect of BTX injection in limbs was transient weakness in injected or neighboring muscles.
Author Affiliations
From the Movement Disorders Group, Department of Neurology, College of Physicians and Surgeons of Columbia University, New York, NY.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Keir and Giele
Hand Ther 2009;14:32-38.
ABSTRACT
| FULL TEXT
Effect of Forelimb Use on Postnatal Development of the Forelimb Motor Representation in Primary Motor Cortex of the Cat
Martin et al.
J. Neurophysiol. 2005;93:2822-2831.
ABSTRACT
| FULL TEXT
Musician's dystonia
Pullman and Hristova
Neurology 2005;64:186-187.
FULL TEXT
Botulinum toxin injections in the treatment of musician's dystonia
Schuele et al.
Neurology 2005;64:341-343.
ABSTRACT
| FULL TEXT
Corticospinal System Development Depends on Motor Experience
Martin et al.
J. Neurosci. 2004;24:2122-2132.
ABSTRACT
| FULL TEXT
Botulinum Toxin Type A Neuromuscular Blockade in the Treatment of Equinus Foot Deformity in Cerebral Palsy: A Multicenter, Open-Label Clinical Trial
Koman et al.
Pediatrics 2001;108:1062-1071.
ABSTRACT
| FULL TEXT
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor
Brin et al.
Neurology 2001;56:1523-1528.
ABSTRACT
| FULL TEXT
Botulinum toxin and spasticity
DAVIS and BARNES
J. Neurol. Neurosurg. Psychiatry 2000;69:143-147.
FULL TEXT
Therapeutics in the Management of Spasticity
Gelber and Jozefczyk
Neurorehabil Neural Repair 1999;13:5-14.
ABSTRACT
|
